ACT	adjuvant chemotherapy
AFP	alpha-fetoprotein
BRAF	B-Raf proto-oncogene (serine/threonine kinase)
BTC	biliary tract cancer
CA19-9	carbohydrate antigen 19-9
CEA	carcinoembryonic antigen
cfDNA	cell-free DNA
CH	clonal hematopoiesis
CHIP	clonal hematopoiesis of indeterminate potential
CRC	colorectal cancer
ctDNA	circulating tumor DNA
ddPCR	droplet digital PCR
DFS	disease-free survival
EGFR	epidermal growth factor receptor
GEJ	gastroesophageal junction
GI	gastrointestinal
HCC	hepatocellular carcinoma
IDH1	isocitrate dehydrogenase 1
LOD	limit of detection
LoQ	limit of quantification
mCRC	metastatic colorectal cancer
MRD	minimal/molecular residual disease
mRD	molecular residual disease
MSI	microsatellite instability
nCRT	neoadjuvant chemoradiotherapy
OS	overall survival
PDAC	pancreatic ductal adenocarcinoma
PET	positron emission tomography
PET/CT	positron emission tomography/computed tomography
PFS	progression-free survival
RAS	RAS oncogene family (KRAS/NRAS/HRAS)
RECIST	Response Evaluation Criteria in Solid Tumors